SCHEDULE: Armistice Capital Discloses 9.99% Stake in Imunon, Inc.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 396,718 shares, representing 9.99% of Imunon, Inc.'s common stock, as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, indicating their beneficial ownership of 396,718 shares of Imunon, Inc. common stock.
• This holding represents 9.99% of the total class of securities.
• The filing is an amendment to a previous filing, with the event date requiring this statement being March 31, 2026.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on existing ownership rather than new developments, financial performance, or strategic shifts.

Positives

• Significant stake of 9.99% held by Armistice Capital, LLC and Steven Boyd, indicating investor confidence.
• The filing is an amendment, suggesting ongoing monitoring and reporting of the investment.

Negatives

• The Master Fund disclaims beneficial ownership due to its investment management agreement with Armistice Capital, which could imply a lack of direct control over voting or disposition of shares by the fund itself.

Risks

• Potential for increased scrutiny from the market or regulators due to the significant ownership stake.
• The filing does not detail specific strategic intentions, leaving room for speculation about future actions by the reporting persons.

Future Outlook

No specific forward-looking statements or guidance are provided in this Schedule 13G filing, which primarily reports on beneficial ownership.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Armistice Capital's increased interest in Imunon, Inc., a move that often precedes further strategic engagement or activism.

Stakeholder Impact

• Shareholders may see increased market interest in Imunon, Inc. due to the significant stake held by a known investment firm.
• Management of Imunon, Inc. will be aware of the substantial ownership by Armistice Capital, potentially influencing strategic decisions.

Next Steps

• Continued monitoring of Imunon, Inc. by Armistice Capital, LLC and Steven Boyd.
• Potential for future amendments to this Schedule 13G if ownership levels change.

Key Dates

Keywords

Schedule 13G, Imunon, Inc., Armistice Capital, LLC, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Investment Management